Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...
Zacks.com on MSN1d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaGSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...
Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...
Theratechnologies (NASDAQ:THTX) has resubmitted its supplemental Biologics License Application for a simplified dosing formulation of its drug tesamorelin for the reduction of excess abdominal fat in ...
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug ...
On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...
Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback